Related Experiment Video

Updated: Aug 13, 2025

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

17.7K

Ferric derisomaltose therapy and heart failure: implications and molecular insights

Konrad T Sawicki1,2, Hossein Ardehali1,2

  • 1Feinberg Cardiovascular and Renal Research Institute, Northwestern University, Chicago, IL, USA.

Nature Cardiovascular Research
|January 23, 2023
PubMed

Insights

Iron deficiency is common in heart failure with reduced ejection fraction (HFrEF). Intravenous iron repletion is being explored to improve outcomes, but current evidence remains inconclusive.

Area of Science:

  • Cardiology
  • Biochemistry

Background:

  • Iron is vital for myocardial energy production and cardiovascular protein synthesis.
  • Iron deficiency affects nearly 50% of patients with heart failure with reduced ejection fraction (HFrEF).
  • Intravenous iron repletion is a potential therapeutic strategy for HFrEF.

Purpose of the Study:

  • To evaluate the efficacy and safety of intravenous iron therapy in patients with HFrEF.

Main Methods:

  • Review of existing clinical trials and observational studies on intravenous iron in HFrEF.
  • Analysis of patient data regarding iron status, treatment, and cardiovascular outcomes.

Main Results:

  • Data on intravenous iron therapy in HFrEF have yielded mixed results.
  • Further research is needed to clarify the role of iron repletion in HFrEF management.

Conclusions:

  • The therapeutic benefit of intravenous iron in HFrEF requires further investigation.
  • Personalized approaches to iron management in HFrEF may be necessary.

More Related Videos

Author Spotlight: Advantages of Pressure-Volume Loop Measurement Method in Cardiovascular Research04:27

Author Spotlight: Advantages of Pressure-Volume Loop Measurement Method in Cardiovascular Research

Published on: January 12, 2024

568
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

713

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
20
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
22
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
664
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
24
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481